TITLE

Memantine: A Review of its Use in Moderate to Severe Alzheimer's Disease

AUTHOR(S)
McKeage, Kate
PUB. DATE
October 2009
SOURCE
CNS Drugs;2009, Vol. 23 Issue 10, p881
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study that investigates the efficacy of memantine in people with moderate to severe Alzheimer's disease. This study showed that combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all domains. In management of patients with moderate to severe Alzheimer's disease, it found that memantine provides an effective treatment option.
ACCESSION #
44255257

 

Related Articles

  • Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Zetterberg, Henrik; Mattsson, Niklas; Blennow, Kaj; Olsson, Olsson // Alzheimer's Research & Therapy;2010, Vol. 2 Issue 6, p1 

    In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment...

  • Improving Drug Trials for Mild to Moderate Alzheimer's Disease. Hogan, David B. // Canadian Journal of Neurological Sciences;Mar2007 Supplement 1, Vol. 34, pS97 

    The article focuses on concerns raised in literature about the design and methodology of drug trials for mild to moderate Alzheimer's disease. The article also make recommendations to deal with the limitations of the clinical trials. Concerns include undue focus on statistical rather than...

  • Promising Alzheimer's Drug Fails.  // MondayMorning;3/8/2010, Vol. 18 Issue 9, p3 

    The article reports that the drug, dimebon, for treating Alzheimer's disease, failed in the initial stage of its clinical trial. It informs that dimebon showed no effect after six months in treating Alzheimer's disease. Earlier trials were successful and dimebon worked really good and showed...

  • Caution with complementaries for cognitive impairment. Harvey, Ken; Stough, Con // Australian Prescriber;Feb2011, Vol. 34 Issue 1, p19 

    As the Australian population ages the burden of dementia is increasing. Conventional drug treatment only provides modest benefits for patients, so patients and their carers often turn to complementary medicines. Early trials showed promise for some compounds but larger better conducted studies...

  • Costs of Mini Mental State Examination-related cognitive impairment. Jönsson, L.; Lindgren, P.; Wimo, A.; Jönsson, B.; Winblad, B.; Jönsson, L; Jönsson, B // PharmacoEconomics;1999, Vol. 16 Issue 4, p409 

    Objective: To investigate the relationship between cognitive impairment, measured with the Mini Mental State Examination (MMSE), and the cost of care.Design: The study uses data from the Kungsholmen project, a population-based study in Sweden in which people 75 years...

  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations. SCHNEIDER, L. S. // Journal of Nutrition, Health & Aging;Apr2010, Vol. 14 Issue 4, p295 

    Recommendations for clinical trials methods for ‘pre-dementia,’ ‘prodromal,’ or early Alzheimer’s disease are discussed. Early AD can be considered as subsets of both ‘amnestic MCI’ and ‘probable AD.’ In principle, it can be...

  • Genentech's Alzheimer's antibody trial to study disease prevention. Garber, Ken // Nature Biotechnology;Aug2012, Vol. 30 Issue 8, p731 

    The article focuses on a clinical trial to be conducted by Genentech Inc., the Banner Alzheimer's Institute and the U.S. National Institutes of Health to investigate Genentech's experimental drug crenezumab efficacy to forestall Alzheimer's disease in healthy individuals. The clinical trial will...

  • Anatabloc Gains Approval for First Human Clinical Study.  // Journal of Gerontological Nursing;Aug2012, Vol. 38 Issue 8, p5 

    The article reports that Rocks Creek Pharmaceuticals Inc. has received an approval to begin a human clinical study on the safety and efficacy of the nutritional supplement Antabloc in individuals with Alzheimer's disease (AD).

  • Does analysis using "last observation carried forward" introduce bias in dementia research? Molnar, Frank J.; Hutton, Brian; Fergusson, Dean // CMAJ: Canadian Medical Association Journal;10/7/2008, Vol. 179 Issue 8, p751 

    The article discusses the disadvantages of using last observation carried forward analysis in dementia research. Last observation carried forward is the very common technique applied in intention-to-treat analyses in trials of dementia drugs. The studies using the technique show higher dropout...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics